Journal of Cardiac Failure

Original peer-reviewed research & reviews #HeartSuccess @HFSA @JHeartFailureS @ElsevierConnect
Co-EIC: @robmentz & @dranulala
YouTube:

[Journal of Cardiac Failure @JCardFail]

We are proud of the progress reflected in this year’s Impact Factor of 9.9, but even more proud of what all of this represents.

A heartfelt THANK YOU to our entire JCF Family. Your engagement as authors, reviewers, readers, and mentors continues to drive this collective success.

[Journal of Cardiac Failure @JCardFail]

Editorial perspective 📝

SURPASS highlights the promise of Impella 5.5 as a bridge to recovery, transplant, or durable LVAD. But important questions remain!

Patient selection, timing, & support strategy may be just as important as the device itself.

🔗https://t.co/I4CMV9as5a

[Journal of Cardiac Failure @JCardFail]

New science 🚨: Impella 5.5 for HF-related cardiogenic shock 🫀

In the SURPASS registry (n=444), survival to discharge was 75% overall & 86.5% with Impella 5.5 alone. Patients bridged to transplant/LVAD had excellent outcomes, with >93% survival.

🔗https://t.co/SNwdge24dD

[Journal of Cardiac Failure @JCardFail]

🫀 Infiltrative & inflammatory cardiomyopathies share common pathways of dysfunction. Advanced imaging is shifting from structure→biology. Probing inflammation, microvascular dysfunction, and energetics to refine diagnosis and guide precision HF care.

https://t.co/B47XDcT9p2

[Journal of Cardiac Failure @JCardFail]

Last call! 🚨 Submissions close today for JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture. Don’t miss the opportunity to contribute at this defining moment in HF care. 🫀

https://t.co/lo4IS3YS81

#HeartFailure #AIinHealthcare #CallForPapers

[Journal of Cardiac Failure @JCardFail]

What's new in heart failure research?

Find out in the June edition of JCF, featuring expert perspectives advancing our understanding of heart failure and informing patient care.

Read the full issue: https://t.co/57AlG1oPlT

[Journal of Cardiac Failure @JCardFail]

Time is running out to submit to JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture.

If your work advances responsible innovation in HF care, now is the time to contribute.⌛

🗓️ Deadline: June 15th, 2026

https://t.co/lo4IS3YS81

#AIinHealthcare

[Journal of Cardiac Failure @JCardFail]

In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%).

Benefits on CV outcomes were consistent across kidney function, even in advanced CKD.

Improves not just CV outcomes but has renal benefits🫀🧪

https://t.co/Bw3XMvW03l

[Journal of Cardiac Failure @JCardFail]

Cardiac sarcoidosis: beyond steroids?

The REPAIR-CS trial is testing rilonacept (IL-1 blockade) added to standard therapy, with FDG-PET inflammation as the primary endpoint—marking a shift toward targeted, mechanism-based treatment.🫀

🔗 https://t.co/Mh3Pgtfhlq

[Journal of Cardiac Failure @JCardFail]

But what does a positive biopsy mean?

The editorial notes no association with outcomes, small high-risk subgroups & lack of genetic testing.

EMB may be most valuable earlier, when diagnosis is uncertain and results can change management. 🔍

https://t.co/UOOIGUBq2w

[Journal of Cardiac Failure @JCardFail]

When should we biopsy for cardiac sarcoidosis? In ILLUMINATE-CS, EMB positivity (~22%) was directionally associated with established predictors (MIDFIN). Novel predictors: septal thickness, FDG-PET burden, BNP). EMBx yield rose stepwise with number of criteria.

🧵

[Journal of Cardiac Failure @JCardFail]

https://t.co/NnAWV2qlWU

[Journal of Cardiac Failure @JCardFail]

The latest State of the Art Review looks at Immune-mediated pericardial & myocardial syndromes as unified spectrum: linking 🧬 susceptibility, 🌍 triggers & systemic inflammation, with integrated diagnostics & expanding therapies (incl. biologics).

🔗 https://t.co/7nE7hAHoCR

[Journal of Cardiac Failure @JCardFail]

Do we always need CMR or biopsy in myocarditis?

Accompanying editorial suggests not, questioning their added prognostic value in lower-risk cases & emphasizing simple, accessible tools like echo for risk stratification.

Time to rethink the approach?🔍

https://t.co/YZtBBQWLVH

[Journal of Cardiac Failure @JCardFail]

Acute myocarditis: who is truly at risk?

In a real-world cohort, most patients had favorable outcomes (~88% event-free at 10 yrs).

But higher risk was linked to age, HF symptoms and LV hypokinesia, highlighting the value of early bedside assessment.🫀📊

https://t.co/lTnRvz2lli

[Journal of Cardiac Failure @JCardFail]

🔗 https://t.co/8QW8bx7Jw4

[Journal of Cardiac Failure @JCardFail]

⬆️ GDF-15 = ⬆️ risk in HFrEF.

In DAPA-HF, dapagliflozin benefit was consistent across GDF-15 levels, but absolute risk reduction was greatest in those with ⏫ levels. Further, dapa did not significantly ⬇️ GDF-15!

GDF-15 is a marker of risk, not response. 🧪🫀

🧵👇

[Journal of Cardiac Failure @JCardFail]

Does sex influence kidney outcomes after heart transplant?

In >30K patients, sex was not associated with early or late kidney failure. Rates of early kidney failure increased after the 2018 allocation change, and this was not impacted by sex. 🫀📊

🔗 https://t.co/isIy0sT5bM

[Journal of Cardiac Failure @JCardFail]

Severe VHD causes ~4% of cardiogenic shock cases, but with ~40% mortality.

In a multicenter cohort from CCCTN ~1/3 underwent valve intervention, with lower mortality vs conservative care, highlighting a high-risk but potentially treatable subgroup🫀⚠️

🔗 https://t.co/BumjMNLx3m

[Journal of Cardiac Failure @JCardFail]

Is HFmrEF a distinct entity? 🫀

Evidence suggests it more closely resembles HFrEF—but it may also represent:
• An overlap phenotype
• A transition state (toward HFimpEF or progression from HFpEF)

EF-based categories remain imperfect—but clinically useful. 💡

[Journal of Cardiac Failure @JCardFail]

HF with mildly reduced EF (HFmrEF) sits between HFrEF & HFpEF; where does it truly belong?

A new HFSA Scientific Statement examines its epidemiology & pathophysiology & provides a comprehensive management framework for this understudied HF phenotype🫀

🔗 https://t.co/pP2WihJQxc

[Journal of Cardiac Failure @JCardFail]

Management remains challenging: no trials specifically target HFmrEF.

This HFSA Statement offers a practical framework using available evidence, and highlights key knowledge gaps to guide future research in this growing HF population. 📊